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Abstract: Dopamine-glutamate interplay dysfunctions have been suggested as pathophysiological
key determinants of major psychotic disorders, above all schizophrenia and mood disorders. For the
most part, synaptic interactions between dopamine and glutamate signaling pathways take part in
the postsynaptic density, a specialized ultrastructure localized under the membrane of glutamatergic
excitatory synapses. Multiple proteins, with the role of adaptors, regulators, effectors, and scaffolds
compose the postsynaptic density network. They form structural and functional crossroads where
multiple signals, starting at membrane receptors, are received, elaborated, integrated, and routed
to appropriate nuclear targets. Moreover, transductional pathways belonging to different receptors
may be functionally interconnected through postsynaptic density molecules. Several studies have
demonstrated that psychopharmacologic drugs may differentially affect the expression and function
of postsynaptic genes and proteins, depending upon the peculiar receptor profile of each compound.
Thus, through postsynaptic network modulation, these drugs may induce dopamine-glutamate
synaptic remodeling, which is at the basis of their long-term physiologic effects. In this review, we
will discuss the role of postsynaptic proteins in dopamine-glutamate signals integration, as well as the
peculiar impact of different psychotropic drugs used in clinical practice on postsynaptic remodeling,
thereby trying to point out the possible future molecular targets of “synapse-based” psychiatric
therapeutic strategies.
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1. Introduction
The post-synaptic density (PSD) is a specialized matrix located at excitatory post-synaptic
terminals with a disc-shaped aspect, a surface area of 0.07 µm2 and a thickness of 30–40 nm at
the electron microscopy [1].
The PSD can be described as a macromolecular complex of several hundreds of proteins acting as
a molecular switchboard of multiple interacting neurotransmitter signaling pathways [2–4].
Results from PSD preparations obtained with different proteomic purification essays have
revealed that more than 400 proteins can be regularly found by mass spectrometry fingerprinting
in the PSD proteome [5]. These proteins include: membrane receptors and channels, signaling
proteins, scaffold and anchoring proteins, GTPases and regulator proteins, kinases, and phosphatases,
cytoskeleton proteins [1,6,7].
PSD molecules are involved in several functions critical to dopamine and glutamate-dependent
synaptic plasticity processes at glutamatergic synapses [8,9]. Indeed, N-Methyl-D-Aspartate (NMDA)
receptors represent the core of this protein mesh, whilst non-NMDA ionotropic and metabotropic
glutamate receptors are located at the edge of the PSD [1]. Specifically, glutamatergic receptors are
targeted at the postsynaptic membrane by PSD multiprotein complexes that regulate their clustering,
signal-transduction activity and therefore synaptic rearrangements [10].
Intriguingly, mass spectroscopy evaluations have provided the possibility to compare protein
expression with protein phosphorylation data regarding the composition of the PSD proteome obtained
from rodent cerebral tissue [11]. It has, therefore, been found that the PSD shows regional differences,
especially in terms of protein phosphorylation that is relatively higher in the hippocampus [11].
Moreover, it has been recently reported that microRNAs (miRNAs) precursors can be detected within
synaptic fractions tightly associated with the PSD, where they play a role in the direct or indirect
regulation of membrane receptors expression [12,13]. Altogether, these findings may reflect regional
variations in the molecular mechanisms underlying synaptic plasticity processes in different areas of
the brain.
Scaffold molecules at the PSD are major players in the regulation of synaptic plasticity processes.
Indeed, by linking the different components of glutamate receptor complexes and by regulating
glutamate receptor trafficking, scaffold proteins modulate the signaling cascade starting from
membrane receptors and ultimately regulate dendritic structure and function [4,14].
Within the scaffold protein subset, the NMDA receptor and type I metabotropic glutamate
receptor (mGluR1/5) scaffold members of the membrane-associated guanylyl kinase (MAGUK) family,
the Homer and the ProSAP/Shank (SH3 domain and ankyrin repeat-containing protein) families of
proteins are the molecules that have mostly attracted study since the accumulating evidence of their
direct involvement in synaptic plasticity processes [4,15].
Proteins containing the PSD-95/disc large/zonula occludens-1 (PDZ) domain are considered a
hallmark of the PSD, and the MAGUKs, including PSD-95, SAP102 and PSD-93, comprise three PDZ
domains in their N-terminus followed by a src homology-3 (SH3) domain and a guanylate kinase
(GK) domain in the C-terminus [16]. PDZ domains are peptide-binding domains, which allow the
above-mentioned proteins to interact with a variety of binding partners within the PSD, such as NMDA
receptors, as well as cytoplasmic proteins [17]. Moreover, it has been shown that PSD-95 may interact
with dopamine and serotonin receptors and regulate their activation state [18,19]. Therefore, MAGUKs
participate to the formation of protein complexes within the PSD by assembling in multimers that
stabilize membrane receptors and provide a physical link between receptors and intracellular molecules
at the crossroad among glutamatergic, dopaminergic, and serotonergic signaling pathways [6,9].
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The other well-known family of PSD scaffolds is the ones of the Homers, which is composed by
three isoforms in mammals (Homer 1, Homer 2, and Homer 3) and takes part to a variety of biological
functions within the PSD [20]. To note, Homer isoforms include two inducible, non-multimerizing
splice variants (namely, Homer 1a and Ania-3), which lack the C-terminal domain and are expressed
in an immediate-early gene fashion secondary to a variety of neuronal stimuli [20]. Particularly,
Homer 1a acts like a dominant negative since it lacks the oligomerization domain and disrupts long
Homer-mediated clusters that anchor type I mGluRs to NMDA receptors and bridge mGluRs to
their intracellular downstream effectors [21,22]. Therefore, Homers long versus inducible isoforms
expression pattern plays a central role in the modulation of the cross-talk between the glutamatergic
and different neurotransmitter signaling pathways, in the regulation of intracellular Ca2+ dynamics
and, ultimately, in dendritic spine remodeling [20,23].
Finally, the ProSAP/Shank family of proteins is composed by Shank 1, Shank 2, and
Shank 3, which are considered key organizing PSD scaffolds implicated in modulating glutamate
neurotransmission [14,24]. Particularly, Shank proteins allow the formation of polymeric network
complexes that require the assembly of Homer tetramers and have been proposed to build functional
platforms for other PSD proteins [25].
Indeed, affinity-purified complexes obtained from PSD fractions have been described to include
2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid (AMPA) receptor subunits (GluR1, GluR2,
GluR3, GluR4), subunits of the NMDA receptor (NR1, NR2A, NR2B), G protein regulators and scaffolds
such as PSD-95, Shank 2, Shank 3, and Homers [26].
PSD proteins have been crucially involved also in direct interactions amongst membrane
receptors. Indeed, growing evidence has been accumulating demonstrating complex connections
between glutamatergic and dopaminergic receptors, which implicate imbricated interactions
with PSD structures (see [23] for a review). Lee et al. [27], for instance, have reported direct
co-immunoprecipitation of NMDA glutamate and D1 dopamine receptors in both hippocampal
and striatal cultures. Moreover, the manipulation of either NMDA or D1 receptor may reciprocally
influence each other’s functions [28]. However, the scaffolding protein PSD-95 seems to be crucially
required for D1 dopamine receptors in order to modulate NMDA currents [29], as well as PSD-95 has
been described to directly regulate NMDA functions by abolishing the NMDA-mediated inhibition of
D1 receptors internalization [18].
Interestingly, PSD molecules have been implicated also in the fine modulation of transductional
pathways starting at dopamine D3 receptors, a subtype of dopamine receptors which has gained
increasing interest because of its role in schizophrenia, drug addiction, and antipsychotics mechanisms
of action [30]. Peculiarly, the expression of D3 receptors has been demonstrated to be regulated
by Brain-Derived Neurotrophic Factor (BDNF) in the nucleus accumbens during development and
adulthood [31], a feature that tightly links these receptors to the developmental pathogenetic hypothesis
of psychosis and depression, as well as the selective expression of D3 receptors in proliferative zones
of striatal granule cells during embryonic development [32].
At the synaptic level, D3 receptors have been found surprisingly located in asymmetric
synapses at the head of dendritic spines [33], differently from D1 and D2 receptors that are
diffused all over dendrites in striatum, and this peculiar localization suggests direct interaction
with NMDA and AMPA glutamate receptors at postsynaptic sites [34]. Indeed, D3 receptors
may bind calcium/calmodulin-dependent protein kinase (CaMKII) in the PSD-enriched nucleus
accumbens neurons and the activation of NMDA receptors may stimulate D3 function by increasing
calcium-dependent CaMKII activation [35]. The modulation of D3 receptors function by PSD is also
suggested by a direct impact of D2/D3 selectively binding antipsychotics, such as amisulpride, on the
expression of PSD genes [36,37].
Clinical and preclinical studies have extensively provided evidence of abnormal expression
and/or functioning of various PSD proteins in diseases such as schizophrenia, bipolar disorder, and
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autism [9,38–40]. These findings are not surprising considering the master role of the above-mentioned
molecules in synaptic plasticity processes that are considered aberrant in neuropsychiatric diseases [41].
Due to the studies conducted so far, showing that PSD molecules are modulated by
antipsychotics [37,42,43] and play a key role in behavioral conducts [44,45], these molecules are
gaining relevant interest as putative targets of pharmacological strategies. However, there are still
potential limitations that may apparently prevent large-scale development of PSD protein-targeted
therapeutic devices.
Despite strong genetic evidence [46], the specific role of PSD molecules in the pathophysiology
(and putatively in therapeutics) of psychiatric diseases is still elusive. One possible hypothesis is
that PSD molecules may concur to synaptic pathology in multiple psychiatric conditions, such as
autism [47], schizophrenia [48,49], or mood disorders [50]. According to this view, in schizophrenia
post-mortem brain tissue an altered expression of proteins belonging to the PSD fraction it has been
observed, leading to the conclusion that, within the PSD, NMDA-interacting, and endocytosis-related
proteins contribute to schizophrenia pathophysiology [49]. Moreover, transgenic animal models
carrying mutations in the genes coding for PSD molecules exhibit clear behavioral phenotypes relevant
to psychopathological conditions in psychiatric diseases [51–54]. Genetic manipulations of PSD
molecules cause dendritic spine defects, which are putatively the basis for behavioral aberrations
relevant to psychiatric diseases [55,56]. This increasing body of evidence supports the view that PSD
proteins are crucially implicated in aberrant synaptic plasticity, and thereby in high-order cognitive
alterations, which are the core of pathophysiology in psychiatric diseases.
Here we review the latest studies regarding the role of PSD molecules in the mechanisms
of action of the psychopharmacologic drugs mainly used in the treatment of major psychiatric
disorders. Moreover, we will explore possible new avenues in the horizon of “PSD-targeting”
therapeutic strategies.
2. Involvement of PSD Molecules in Psychiatric Drugs Mechanisms of Actions
Consistent with the crucial position of postsynaptic proteins at the crossroads of transductional
pathways implicated in synaptic plasticity, several studies have demonstrated their central role in the
mechanisms of action of drugs currently considered as the mainstay treatment of major psychiatric
disorders, such as antipsychotics, antidepressants, and mood stabilizers (Figure 1).
2.1. Antipsychotic Drugs
Since the very early studies on the impact of antipsychotic treatment on the brain it was clear that
these drugs may induce ultrastructural changes in both cortical and subcortical glutamatergic synapses
with significant differences between first generation (FGA) and second generation antipsychotics
(SGA) [57–59]. Moreover, early studies by de Bartolomeis’s laboratory team demonstrated that both
FGAs and SGAs may directly impact the scaffolding proteins that constitute the architecture of PSD
via differentially inducing, in both acute and chronic paradigms, the expression of the immediate-early
gene Homer 1a [60,61]. Particularly, the specific perturbation of dopaminergic signaling may lead to
concurrently specific differential topographical brain expressions of Homer family PSD genes directly
depending on the receptor profile of the antipsychotic [62], thereby suggesting Homer as a molecular
marker of glutamatergic impact by antipsychotics. PSD molecules directly linked to glutamate NMDA
receptors, such as PDS95, have been demonstrated to be modified by FGAs and SGAs [63]. More
recent studies specifically correlated the impact of SGAs on PSD-95 with their ability to modulate
serotonergic neurotransmission together with dopaminergic one [64].
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Figure 1. Schematic representation of how postsynaptic density (PSD) proteins elaborate and
integrate multiple transductional pathways starting at main dopamine and glutamate membrane
receptors. Scaffolding proteins (Homer, Shank, PSD-95) physically connect receptors, linking them
to intracellular calcium stores. Transductional pathways activated by dopamine receptors closely
interconnect with glutamatergic ones via key PSD proteins, such as GSK3, which elaborates and
regulates neuronal survival and differentiation. All transductional pathways route receptors signaling
to appropriate nuclear targets via specific effectors, such as CaMK, MAPKs, or Erk, in order to finely
modulate long-term activity-dependent neuronal rearrangements. The call-outs describe the impact
on some crucial PSD molecules by psychopharmacologic drugs, as discussed in the text. NMDAR,
N-methyl-D-aspartate glutamate receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid glutamate receptor; mGluR1a/5, metabotropic glutamate receptor type 1a/5; TARP, transmembrane
AMPA receptors re ulatin protein or stargazin; PSD-95, postsynaptic ensity protein 95kD; DISC1,
disrupted in schizophrenia 1; GSK3, glycogen synthase kinase 3; PDE4, phosphodiesterase 4;
GKAP, guanylate kinase associated protein; H1a, Homer1a immediate-early inducible protein; PIP2,
phosphatydilinositol bisphosphate; DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; cAMP, cyclic
adenosine monophosphate; ER, endoplasmic reticulum; PLC, phospholipase C; PKC, protein kinase C;
PKA, protein kinase A; CAMK, calcium-calmodulin regulated kinase; MAPKs, mitogen-activated protein
kinases; Erk, extracellular signal-regulated kinase; MEK, MAPK/Erk kinase; and Rac1, Ras-related C3
botulinum toxin substrate 1.
The effects of antipsychotics on PSD molecules are so specific that the topographical pattern of
PSD genes expression may vary with the dose of the antipsychotic administered: indeed, increasing
doses of selected FGAs or SGAs may progressively recruit the expression of crucial PSD genes, such
as Zif268, Homer1a, Arc, and c-fos, while gradually impacting selected brain areas [42]. Moreover, the
common clinical practice of switching antipsychotic has been demonstrated to specifically perturb
PSD molecules depending on the specific switch procedure (especially FGA to SGA, or vice versa) [37].
Therefore, antipsychotics may basically modify the architecture of the synapse through
determining rearrangements of a complex calcium-regulated network with the final aim of integrating
and routing both dopaminergic and glutamatergic signaling pathways to appropriate nuclear targets,
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therefore, finally impacting the intrinsic functions of synapses in selected brain areas [23]. Recent
researches, indeed, pointed out the essential role of PSD molecules in the morphologic changes
of dendritic spines induced by long-term antipsychotic treatment [65]. Moreover, a crucial role of
microRNAs interactions with PSD molecules has been suggested in the radical synaptic plasticity
rearrangements induced by antipsychotics [66].
2.2. Mood-Stabilizing Drugs
Several studies have demonstrated that mood stabilizing drugs, although very different amongst
each other in chemical structure and mechanisms of action (especially lithium vs. valproate), may
share a common impact on crucial components of post-receptor transductional pathways, such as
the glycogen synthase kinase 3β (GSK3β) or the mitogen-activated protein kinases (MAPKs) [67].
Both lithium and valproate, by acting on those molecules, may control glutamatergic signaling via
reducing membrane insertion of AMPA glutamate receptors through the regulation of GluR1 AMPA
subunits phosphorylation status [68]. A similar action has been described for NMDA glutamate
receptors, whose membrane insertion may be controlled by lithium through a direct action on NR2A
phosphorylation and its interaction with PSD95 [69]. The impact of both lithium and valproate on
GSK3β has been associated to a long-term increase in hippocampal synapse formation and connections,
which could be directly correlated to mood stabilizing effects [70].
More recent studies demonstrated that chronic treatment with both lithium and valproate may
affect the expression of genes coding for structural proteins of postsynaptic density, such as Homer 1b/c,
Shank and Inositol-1,4,5 trisphosphate receptors (IP3Rs), which all represent a putative connection between
glutamatergic and dopaminergic function as a further mood-stabilizing mechanism [71]. Moreover,
when added to antipsychotics (such as it frequently occurs in clinical practice), mood stabilizers may
induce a differential modulation of PSD molecules as compared to the effects of individual drugs in
both cortical and subcortical brain regions [72]. Indeed, a growing body of evidence suggests a direct
impact of mood stabilizers on dopaminergic neurotransmission [73], as well as that PSD molecules
represents crucial dopamine-glutamate crossroads for the combined actions of mood stabilizers and
antipsychotics [74].
Other mood stabilizers, such as carbamazepine and lamotrigine, although not sharing a common
action on GSK3β as lithium and valproate, have been demonstrated to impact inositol pathways
and MAPK cascades, which also represent core crossroads of dopamine-glutamate postsynaptic
interplay [75,76].
2.3. Antidepressant Drugs
A complex dysfunction in synaptic plasticity of specific brain areas, such as the hippocampus and
prefrontal cortex, is a well-known pathophysiological mechanism in depression [77]. Human studies
have demonstrated that glutamate neurotransmission is impaired in cortical subregions in subjects
suffering from major depression, with higher levels of NMDA receptors subunits in frontal cortex
and even higher NMDA levels in parietal cortex in suicide completers, as well as reduced levels in
dorsolateral prefrontal cortex and higher PSD-95 levels in anterior cingulate [78].
Chronic antidepressant treatment may induce morphological changes in the abovementioned
brain areas through the direct modulation of PSD proteins. Indeed, fluoxetine has been demonstrated
to increase the expression of hippocampal PSD95 and AMPA receptors subunit GluR1 via a mechanism
involving TrkB receptors of BDNF [79]. Changes in both NMDA and AMPA receptors subunits
provoked by chronic fluoxetine have been associated with forebrain up-regulation in dendritic spines
and formation of mushroom-type spines [80]. Based on those observations regarding glutamate
neurotransmission modulation by antidepressants, some studies have demonstrated that also serotonin
receptors-modulating antipsychotics, such as lurasidone, may provoke hippocampal PSD proteins
modulation and dendritic spines changes similar to that induced by fluoxetine [81]. Additionally,
lurasidone has been demonstrated to exert antidepressant properties through a direct modulation of
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BDNF in prefrontal cortex of animal models of depressive states, thus suggesting a crucial impact of
this drug on pathophysiologic neuroplastic mechanisms underlying depression [82,83]. Moreover,
the concurrent administration of antipsychotics and SSRI antidepressants may induce synergistic
modulation of specific PSD molecules, such as Homer 1a, thereby suggesting a fundamental crosstalk
of serotonin and dopamine transductional pathways in the pathophysiology of depressive states [84].
Core molecules related to dopamine signal transduction, such as DARPP-32 have been reported
to be significantly modulated by antidepressants, as well as the combination of antipsychotics and
antidepressants may synergistically impact synaptic proteins related to energetic metabolism (for a
review see: [74]). The essential role of dopamine modulation in depression, as well as the tight
imbrication with pathophysiologic mechanisms also involved in schizophrenia, may be confirmed by
the fact that dopaminergic antidepressant drugs, such as bupropion, have been demonstrated to be
safe and effective in depressive states occurring in schizophrenic patients [85].
The above described glutamatergic postsynaptic mechanisms have been reported to be on the
basis of the rapid antidepressant properties displayed by ketamine, an NMDA antagonist. Indeed,
ketamine has been demonstrated to induce hippocampal PSD-95 modulation via the TrkB-BDNF
pathway similar to those provoked by fluoxetine, but in a more rapid and unstable manner [86].
Moreover, the administration of lithium may potentiate the synaptogenic and antidepressant effects
of ketamine by inhibiting GSK3β [87]. Recently, ketamine has been demonstrated to exert its
antidepressant effects essentially via its metabolite hydroxynorketamine. Indeed, the R-enantiomer of
hydroxynorketamine shows behavioral and biochemical antidepressants effects that seem independent
from NMDA receptors’ inhibition, but involve a robust increase in AMPA receptors-mediated
excitatory postsynaptic currents [88]. AMPA receptors, in fact, have been crucially correlated to
the pathogenesis of both psychosis and mood disorders. Early deletion of AMPA GluR1 subunit may
induce striatal hyperdopaminergia and behavioral abnormalities mimicking psychosis [89], as well as
AMPA knockout mice exhibit increased learned helplessness, decreased serotonin and norepinephrine,
and impaired glutamate neurotransmission, all features modeling depressive phenotypes [90].
However, only early impairment of AMPA function has been demonstrated to induce neuropsychiatric
phenotypes, since post-adolescence-induced AMPA ablation results in normal behaviors in animal
models [91,92]. These findings suggest that global dysfunctions of glutamatergic signaling that onset
during early development are necessary to establish full depressive phenotypes. Indeed, ketamine has
been demonstrated to have no effects on juvenile animals, because developmentally mature synapses
are required to induce antidepressant responses [93].
Regarding the role of PSD proteins in the mechanisms of action of glutamatergic antidepressant
drugs, since the modulation of both the GluN2A and GluN2B subunits of the NMDA receptor
has been reported to individually exert antidepressant effects [94], a recent study demonstrated
that the impairment of PSD-95 constitutive functions may impair NMDA-GluN2B-mediated
antidepressant-like responses [95].
PSD molecules involvement in major neuropsychiatric disorders and their modulation by main
psychopharmacologic drugs are summarized in Table 1.
3. Novel Putative Therapeutic Strategies Based on PSD Molecules Modulation
Based on the studies described above, it can be expected that, once the molecular mechanisms
implicated in each distinct psychiatric disease would be at least partially unveiled, modulation of
PSD molecules will be instrumental at restoring physiological synaptic functioning and, consequently,
network connections at micro- and macro-circuit levels. However, as a challenge, the exact brain
division, and even the cellular type, where these molecules operate to modulate definite behavioral
conducts, and to putatively cause aberrations, has not been fully characterized. Nonetheless,
an increasing body of evidence is locating PSD alterations in specific brain sites. In post-mortem brain
samples from schizophrenia patients, significant changes in key PSD molecules (i.e., PSD-95, Homer 1a,
Homer 1b, Preso) have been demonstrated in multiple brain regions, including the hippocampal CA1
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region, the prefrontal cortex, and the olfactory bulb [96]. Exact delivery of PSD-targeting therapeutic
agents in brain subdivisions or cell types implicated in disease pathophysiology may be crucial to
maximize pharmacological efficacy and/or minimize untoward effects. Despite this field still being in
its formative stage, recent novel technological approaches are attempting to overcome the challenges
deriving from cell-type restricted drug delivery within the Central Nervous System (CNS), as in the
case of the recent advent of nanomedicines, which provide potent tools to implement CNS targeted
delivery of active compounds [97]. Great advances are mainly taking place in other biomedical fields,
such as oncology or neurology. One such example is multiple sclerosis, where advanced drug delivery
of the so-called disease-modifying therapies is under thorough investigation in order to decrease
adverse effects, increase drug efficacy, and increase patient compliance through the direct targeting
of pathologic cells [98]. Among advanced drug delivery systems, current studies are accounting for
nanoparticles, microparticles, fusion antibodies, and liposomal formulations. Additionally, there is
increasing efforts to delineate alternative routes of drug administration, such as the nasal route for
systemic use, in order to cross the blood-brain banner (BBB) [99]. A recent report has demonstrated that
the intranasal administration of a sertraline-conjugated small-interfering RNA (siRNA) was effective
in silencing the expression and diminishing the biological function of the serotonin transporter (SERT)
and evoked fast antidepressant-like responses in mice [100]. Overall these breakthrough drug delivery
technologies are aimed at being applicable to multiple disease treatments in the CNS and may allow
to precisely target pharmacological agents to PSD molecules in the cell types where their alterations
participate in pathophysiology of psychiatric diseases.
As a third valuable challenge, it has to be mentioned that as PSD molecules share both
architectural/functional and signaling roles in the post-synaptic neuron, they are simultaneously
recruited in several downstream pathways, often representing sites of trans-activation and intersection
among different intracellular cascades. Therefore, PSD molecules have pleiotropic biological roles
and participate in several downstream pathways concurrently [101,102]. How to selectively target a
distinct PSD protein-operated downstream pathway over the concurrent others is another relevant
field of research. However, PSD molecule-targeting may more easily attain a modulation of selected
downstream pathways compared to receptor-targeting pharmacological devices, possibly representing
one of the major advantage of this novel strategy.
Given all the considerations above, modulation of PSD molecules as a therapeutic strategy
in psychiatric diseases may occur either indirectly or directly. Indirect PSD molecule modulation
intervenes as a consequence of the interaction of a pharmacological agent with their target non-PSD
receptors. Indirect modulation may be regarded as an accessory molecular effect of a drug, which may,
theoretically, be either incidental or desired. However, to date, there are no designed pharmacological
agents whose primary or secondary desirable molecular effects are to specifically modulate PSD
targets. On the other hand, multiple psychotropic pharmacological agents have been demonstrated
to incidentally modulate gene and protein expression of PSD molecules [81], as also described in
sections above. However, this approach has considerable shortcomings. Indeed, a clear demonstration
that this effect is related to antipsychotic efficacy is still lacking. As a second cue, it has been
only partially demonstrated that psychotropic agent-mediated modulation of expression of PSD
molecules may translate in changes at the protein, functional, and behavioral levels. Despite these
considerations, it has to be expected that PSD molecules participate in the biological consequences of
psychotropic agent administration. This statement is supported by experimental evidence showing
that similar modulations of target PSD molecules are the result of different therapeutic procedures.
In a recent report, increased expression of the Homer1a in the medial PFC was associated with
inhibition of depressive-like behaviors and was the ultimate molecular step of various antidepressant
treatments, including sleep deprivation, up-regulation of adenosine 1 receptor, imipramine, or
ketamine administration [103]. Evaluation of the pattern of expression of PSD molecules has also
been suggested to provide information on augmentation or association therapeutic strategies. It has
been reported that Arc expression is differentially modulated by haloperidol alone, or in association
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with minocycline, a synthetic second-generation tetracycline that has been proposed as an adjunctive
treatment mostly for negative symptoms of schizophrenia [104]. In another study, it has been observed
that the molecular changes in targeted PSD molecules are different in relation to the timing and the
order in which antipsychotics are given [37]. Overall, these reports suggest that PSD molecules are
key actors in the mechanisms of action of psychotropic agents and their modulation may represent
one of the ultimate biological steps to trigger pharmacological effects of these drugs. In these terms,
PSD molecule modulation may characterize other recently proposed therapeutic agents that act
on glutamatergic transmission, such as: agonists at group 2/3 metabotropic glutamate receptors;
positive allosteric modulators of type 5 metabotropic glutamate receptors; NMDA receptor modulators;
AMPAkines; or glycine transporter inhibitors [2,105–109]. However, even in these cases, putative
modulation of PSD molecules should be regarded as a secondary, accessory biological effect, whose
actual involvement in these agents’ mechanisms of action is yet to be completely elucidated.
One intriguing novel therapeutic strategy should be represented by direct targeting of PSD
molecules. In this case, the relevant challenge scientists should face is the intracerebral and intracellular
localization of these molecules, which would constrain novel putative pharmacological agents to face a
double barrier, i.e., the blood-brain barrier and the cell membrane. In fact, current agents in neurology
and psychiatry are able to cross the blood-brain barrier, due to their high lipophilicity. Only recently
technological advance has made it possible to develop pharmacological devices with the aptitude
to trespass the neuron cell membrane and interact with protein or genic elements [110]. NA-1 is
a recently described PSD-95 small-peptide inhibitor, which prevents PSD-95 interaction with the
NR2B subunit of NMDA receptors, thereby uncoupling NMDA receptors from nNOS-mediated
downstream neurotoxic signaling pathways [111]. Notably, this uncoupling does not affect NMDA
receptor-mediated excitatory neurotransmission in the brain [111]. NA-1 has been previously tested
in rat and non-human primate models of transient focal ischemia and stroke [112,113]. Subsequently,
this agent has been studied in clinical stroke treatment in humans [114] and is currently undergoing
phase III clinical trials.
NA-1 represents a paradigmatic example of a pharmacological agent, which directly modulates
PSD molecules for the treatment of neuropsychiatric disease. The possibility to expand the therapeutic
use of NA-1 to behavioral diseases appears minimal, since it targets a very restricted downstream
pathway. However, this example opens the way to the possibility of designing small molecule
inhibitors to interact with other portion of PSD-95, or with other PSD molecules, in order to disrupt the
protein-protein interactions and modulate selected downstream pathways implicated in behavioral
disease mechanisms.
Int. J. Mol. Sci. 2017, 18, 135 10 of 21
Table 1. PSD molecules involvement in major neuropsychiatric disorders and their modulation by main psychopharmacologic treatments.




-Major Depressive Disorder [119,120]
-Drug addiction [121–128]
-Chronic inflammatory pain [129,130]
-Fragile X Syndrome [131]
-Alzheimer’s Disease [132]
-Parkinson’s Disease [133,134]
-Traumatic brain injury [135,136]
-Homer 1a may be differentially modulated by both first generation and second generation antipsychotics tightly depending
on their own individual receptor profile [42,61,62,137,138]
-The mood stabilizers lithium and valproate have scarce effects on Homer 1a expression, whereas they deeply impact synaptic
structure conformation by modulating constitutive Homer 1b/c gene expression [71]
-Combination of antipsychotics and mood stabilizers elicits changes in Homer 1a gene expression that are substantially
different from those induced by these drugs individually administered [72]
-Antidepressants and serotonin-modulating antipsychotics induce peculiar cortical expression of Homer 1a in brain regions
relevant for negative and cognitive symptoms of schizophrenia [62,84]
Homer 2 -Schizophrenia [139]-Alcohol abuse [140–142]
-Chronic haloperidol and clozapine administration may induce overexpression of Homer 2 in lateral septum in animal
models [62]
Homer 3 -Cerebellar ataxias [143,144]
PSD-95
-Schizophrenia [46,145]
-Autism Spectrum Disorders [46,146]
-Bipolar Disorder [9,147]
-Major Depressive Disorder [148]
-Lurasidone and fluoxetine decrease PSD-95 expression in prefrontal cortex and hippocampus [81]
-Olanzapine and aripiprazole may reverse the immobilization stress-induced decrease in PSD-95 levels in frontal cortex [149]
-PSD-95 is crucial for serotonin 5HT2A and 5HT2C receptors expression and abolishing its expression in knockout animals
impairs atypical antipsychotics effects [64]
-Ketamine impacts PSD-95 expression in cortical and striatal regions [150], and PSD-95 seems to be crucial for ketamine
antidepressant effects [95]
Shank -Schizophrenia [44,151,152]-Autism Spectrum Disorders [153–155]




-Major Depressive Disorder [158,159]
-Bipolar Disorder [160,161]
-Aripiprazole activates GSK3β signaling in prefrontal cortex and nucleus accumbens, whereas haloperidol activates GSK3β
signaling only in nucleus accumbens [162]
-Paliperidone exerts protective effects on neurons via decreasing glutamate-induced overactivation of GSK3β signaling [163]
-Clozapine may increase GSK3β signaling in prefrontal cortex, but not in striatum, where it is activated by haloperidol [164]
-Fluoxetine and imipramine have scarce effects on GSK3β signaling [164]
-The inhibition of GSK3β signaling seems to be a crucial mechanism explaining mood stabilizing effects of lithium [165]
-Valproate inhibits metamphetamine-induced hyperlocomotion via decreasing GSK3β activity [166]
DISC1 -Schizophrenia [157,167]-Bipolar Disorder [168,169]
-Atypical antipsychotics may increase cortical expression of DISC1, whereas typical antipsychotics have no effects [170]
-Specific genomic variants in DISC1 gene in humans have been associated to ultra-resistance to antipsychotic treatment [171]
CAMKII -Schizophrenia [172]-Major Depressive Disorder [173]
-Clozapine-induced increase in prefrontal cortex activity is crucially mediated by CAMKII-NMDA receptor interactions [174]
-Clozapine, haloperidol and risperidone may decrease CAMKII expression in striatum in animal models [175]
-CAMKII is essential for clozapine-mediated effects on conditioned avoidance responses in animal models [176]
-Fluoxetine may induce changes in CAMKII promoter [177]
Int. J. Mol. Sci. 2017, 18, 135 11 of 21
4. Conclusions
PSD molecules represent crucial crossroads for multiple receptor signaling involved in the
mechanisms of action of the most frequently used psychopharmacologic drugs. Their close
intermingling receives, elaborates, and converges multiple signals to the appropriate nuclear targets,
in order to finely modulate synaptic rearrangements in response to neural activity. However,
PSD molecular mechanisms are so sophisticated and complex that their knowledge is only partial
at the moment. Further studies will putatively permit the development of “synapse-targeting”
psychopharmacotherapeutics, which could finally bypass the pharmacodynamics and pharmacokinetic
problems that currently jeopardize a fully-effective psychopharmacologic treatment.
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